Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › RYTM

SILVERARC CAPITAL MANAGEMENT, LLC position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 348,317 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$33.2M, representing 4.23% of its reported portfolio and ranking #8 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed RYTM holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)348.32K sh
Reported value held$33.17M
Portfolio Weight4.23%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's RYTM position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in RYTM in Q3 2023 at 260,537 shares (US$6.0M). The position peaked in Q3 2025 at 369,996 shares, worth US$37.4M. Across 13 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 348,317 shares valued at US$33.2M — an increase of 36,856 shares quarter over quarter.. Notable position changes include a 38% increase in Q3 2024 (shares rose 7% over the following quarter), a 63% trim in Q4 2025 (shares fell 19% over the following quarter), a 125% increase in Q1 2026 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 260.54K $5.97M New
Q4 2023 174.25K $8.01M Reduce
Q1 2024 183.78K $7.96M Add
Q2 2024 184.66K $7.58M Hold
Q3 2024 255.58K $13.39M Add
Q4 2024 273.90K $15.33M Add
Q1 2025 337.61K $17.88M Add
Q2 2025 400.77K $25.32M Add
Q3 2025 370.00K $37.37M Reduce
Q4 2025 135.95K $14.55M Reduce
Q1 2026 306.00K $26.61M Add
Q2 2026 311.46K $34.58M Add
Q3 2026 348.32K $33.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held RYTM?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed RYTM holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in RYTM?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 348.32K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $33.17M, representing 4.23% of its reported portfolio and ranking #8.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling RYTM?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in RYTM. The position peaked in Q3 2025 at 370.00K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.